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Results Running induced a significant increase in intesti-
nal permeability and serum I-FABP concentration but there 
were no differences between asymptomatic and symptomatic 
runners. Serum LPS activity did not change from baseline 
following the running test but the symptomatic group exhib-
ited higher LPS activity at baseline compared to the asymp-
tomatic runners.
Conclusions Running for 90 min at a challenging pace 
causes small intestinal damage and increases intestinal per-
meability. However, these alterations in GI function do not 
appear to correlate with the development of GI symptoms 
during running.
Keywords Intestinal permeability · Exercise · 
Gastrointestinal symptoms · I-FABP · LPS
Abbreviations
GI  Gastrointestinal
I-FABP  Intestinal fatty acid-binding protein
LPS  Bacterial lipopolysaccharide
Introduction
Exercise-induced gastrointestinal (GI) symptoms such as 
diarrhea, cramping, nausea and gastric pain occur frequently 
in runners during training and competitions. The prevalence 
of GI symptoms during exercise varies across studies with 
estimates ranging from 30 to up to 90% depending on the 
study design (de Oliveira et al. 2014). In addition to the 
high prevalence of these symptoms, exercise-induced GI 
distress may negatively impact athletic performance and in 
some cases, lead to dropping out of the competition (Hoff-
man and Fogard 2011; de Oliveira et al. 2014). However, the 
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the prevalence of exercise-induced GI symptoms is high, 
the mechanisms leading to GI distress during exercise are 
not fully understood. The aim of this study was to iden-
tify running-induced changes in intestinal permeability and 
markers of GI function and investigate their association with 
gastrointestinal symptoms.
Methods We recruited 17 active runners who we allocated 
as either asymptomatic or symptomatic based on their his-
tory of experiencing GI symptoms during running. The par-
ticipants took part in a running test where they were asked 
to run for 90 min at 80% of their best 10 km race speed. 
Intestinal permeability was measured at baseline and after 
the running test. Levels of serum intestinal fatty acid-bind-
ing protein (I-FABP), zonulin, bacterial lipopolysaccharide 
(LPS), and fecal calprotectin were also measured at baseline 
and after the running test.
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mechanisms leading to GI distress are not fully understood, 
nor the reasons why some remain asymptomatic.
Exercise affects GI function via several mechanisms that 
may give rise to exercise-induced GI disturbances. Although 
the etiology of exercise-induced GI disturbances involves 
multiple physiological and pathophysiological mechanisms 
(de Oliveira et al. 2014), studies have suggested that the key 
culprit behind GI symptoms during exercise is splanchnic 
hypoperfusion (ter Steege and Kolkman 2012; van Wijck 
et al. 2012). Splanchnic hypoperfusion during exercise may 
lead to intestinal ischemia that subsequently damages intes-
tinal epithelial cells and compromises the intestinal barrier 
function. So far, multiple studies have reported exercise-
induced increases in intestinal permeability (Oktedalen 
et al. 1992; Pals et al. 1997; van Nieuwenhoven et al. 2004; 
Marchbank et al. 2011; van Wijck et al. 2011; Zuhl et al. 
2015; Davison et al. 2016), serum endotoxemia (Bosenberg 
et al. 1988; Jeukendrup et al. 2000; Ashton et al. 2003), 
and inflammatory markers (Jeukendrup et al. 2000; Gill 
et al. 2015) but whether these changes are due to splanchnic 
hypoperfusion is still unclear. Also, contradictory findings 
exist (Ryan et al. 1996; van Nieuwenhoven et al. 1999; Van 
Wijck et al. 2012) and the association between impaired 
barrier function and GI symptoms during exercise remains 
poorly characterized.
The aim of this study was to measure running-induced 
changes in intestinal permeability and markers of GI func-
tion and investigate their association with gastrointestinal 
symptoms. Intestinal permeability was assessed via oral 
administration of iohexol, a 821 Da sized contrast agent that 
has proved to be a reliable marker of intestinal permeability 
(Halme et al. 1993, 2000; Frias et al. 2014; Forsgård et al. 
2016). We also measured serum concentrations of intestinal 
fatty acid-binding protein (I-FABP), a marker of enterocyte 
damage (van Wijck et al. 2011) and zonulin, an endogenous 
protein that specifically and reversibly regulates intestinal 
permeability (Fasano 2012). In addition, we measured serum 
bacterial lipopolysaccharide (LPS) activity and analyzed 
the level of intestinal inflammation by measuring fecal cal-
protectin concentrations. To our knowledge, this is the first 
study to directly compare alterations in intestinal perme-
ability in asymptomatic and symptomatic runners.
Materials and methods
Ethical statement
The study was conducted in adherence to the ethical 
regulations outlined in the Declaration of Helsinki and 
the study was approved by the Hospital District of Hel-
sinki and Uusimaa (HUS) Coordinating ethics committee 
(13/13/03/00/2015). Informed consent was obtained from 
all individual participants included in the study.
Participants
Study participants were recruited by a recruitment notice 
posted in online groups for active runners around the Hel-
sinki area. Voluntary participants received an informational 
letter about the study, a consent form, and a symptom history 
questionnaire used to determine the participant’s suitabil-
ity for the study. Suitable participants were active runners 
between the age of 18 and 45 who reported to complete at 
least three long-distance runs per week. Consenting volun-
teers suitable to the study were accepted as participants. A 
total of 24 participants were recruited of which 7 dropped 
out due to injury or illness (Fig. 1). Persons with a diagnosed 
gastrointestinal illness or asthma, heart, or cardiovascular 
diseases were excluded from participation. Pregnant or 
breastfeeding women were also excluded as well as persons 
with iodine allergy because of the iohexol used in determin-
ing permeability.
Study protocol
The study participants were first asked to fill out a symp-
tom questionnaire (21 items) that probed the nature and 
frequency of their GI symptoms during running. Based 
on their answers, the participants were allocated into two 
groups: asymptomatic and symptomatic. Participants were 
deemed symptomatic if they reported having GI symptoms 
at least 50% of their runs and asymptomatic if they reported 
experiencing GI symptoms in less than 10% of their runs. 
Baseline samples at rest were collected 3 weeks before the 
running test. On the running test day, intestinal permeability 
Fig. 1  Flowchart showing the number of study participants in each 
step from enrollment to final analyses
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measurement (measurement of intestinal permeability) was 
started before the running test where the participants ran for 
90 min at 80% of their best 10 km race speed (running test). 
A blood sample was withdrawn immediately after the run 
and the participants were asked to collect a fecal sample at 
home. The subjects also received a symptom questionnaire 
(eight items) where they were asked to score on a visual 
analog scale (VAS) how much stomach pain they experi-
enced during the run. The occurrence of other GI symptoms 
was also asked in the symptom questionnaire. The partici-
pants were also given a questionnaire (11 items) where they 
were asked to record all GI symptoms they experience later 
that day. The participants were also instructed to keep a food 
diary for 3 days before the baseline measurements and the 
running test day.
Running test
The subjects ran for 90 min at a challenging pace which 
was suggested as 80% of the speed of their best 10 km race 
time. The effort should have been challenging, but able to 
be maintained for the full 90 min. The running pace was 
determined individually by the athlete according to their 
perceived exertion.
Blood sampling
A blood sample was taken at baseline at rest and then imme-
diately after the running test. The blood sample volume was 
approximately 5 ml. The blood samples were collected in 
serum separation tubes [VenoSafe™ Clot Act. (Z), Terumo 
Europe, Leuven, Belgium] from the median cubital vein by 
a licensed physician. Serum was separated by centrifugation 
(1500g, 10 min), collected and stored at − 80 °C for later 
analysis.
Fecal sample
The study subjects were asked to provide a fecal sample 
at rest 3 weeks before the running test and then after the 
running test. The subjects were given written instructions 
and they collected the fecal samples independently at home 
in a provided specimen container stored at room tempera-
ture. The samples were returned the next day and stored at 
− 20 °C within the same day for later analysis.
Measurement of intestinal permeability
Intestinal permeability was determined through oral admin-
istration of 50 ml 755 mg iohexol/ml solution (Omnipaque 
350™, GE Healthcare, Oslo, Norway) according to a previ-
ously published method (Halme et al. 2000). Briefly, the 
subjects ingested the iohexol solution dissolved in tap water 
after which they collected all excreted urine in a specimen 
container for 24 h. The iohexol concentrations in the urine 
were measured using the iohexol enzyme-linked immuno-
sorbent assay (ELISA) kit (BioPAL, Worcester, MA, USA) 
according to the kit instructions. The intra-assay coefficient 
of variation (CV%) of this assay was 4.8% and the limit of 
detection 0.05 μg/ml. Sample analysis was conducted on 
the same microtiter plate to decrease inter-assay variation.
Measurement of serum I-FABP
Serum I-FABP concentrations were measured using I-FABP 
ELISA test kit (Hycult Biotech, Uden, The Netherlands) per 
the kit instructions. The intra-assay CV% of this analysis 
was 5.2% with a detection limit of 25 pg/ml. Sample analy-
sis was conducted on the same microtiter plate to decrease 
inter-assay variation.
Measurement of serum zonulin
Serum zonulin concentrations were measured using Zonulin 
ELISA test kit (Immunodiagnostik, Bensheim, Germany) 
according to the kit instructions. The intra-assay CV% was 
4.6% and the limit of detection 0.225 ng/ml. Sample analy-
sis was conducted on the same microtiter plate to decrease 
inter-assay variation.
Measurement of serum bacterial lipopolysaccharide
Serum activity of bacterial lipopolysaccharide (LPS) was 
analyzed using LAL (Limulus Amebocyte Lysate) Chromo-
genic Endpoint Assay (Hycult biotech, Uden, The Nether-
lands) according to the kit instructions. The intra-assay CV% 
of the assay is 1.9% and the limit of detection 0.04 EU/ml. 
Sample analysis was conducted on the same microtiter plate 
to decrease inter-assay variation.
Measurement of fecal calprotectin
Fecal calprotectin concentrations were measured using 
Calpro ELISA test (Calpro AS, Oslo Norway) per the kit 
instructions and a BEP 2000 advance ELISA analyzer 
(Siemens Healthcare Diagnostics, Munich, Germany). The 
detection limit of the Calpro ELISA assay in our laboratory 
is 5 μg/g with an intra-assay CV% below 4.6%. All samples 
were analyzed in the same batch and on the same microtiter 
plate to decrease inter-assay variation.
Food diary
The participants were asked to keep a food diary for 3 days 
before the baseline measurements and the running tests. 
The participants were provided with detailed instructions 
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for completion of the food diary. Food diaries were analyzed 
using Fineli Ruokakori (Foodbasket) database (http://www.
fineli.fi/foodbasket.php) for average intake of macronutri-
ents and selected micronutrients over each 3-day food diary 
period. Analysis of the food diary revealed no statistically 
significant differences in the average intake of various nutri-
ents from baseline to the running test day or between the 
groups at these time points (data not shown).
Data analysis
Normality of the data sets was tested with Kolmogo-
rov–Smirnov test and based on these analyses, differences 
between the symptomatic and the asymptomatic groups 
were analyzed using independent samples t test. Changes 
within groups from baseline to after the running test meas-
urements were analyzed using paired samples t test. All data 
are expressed as means ± standard deviations. Statistical cal-
culations were made by PASW Statistics software version 
18.0.2. (IBM, Armonk, NY, USA). Figures were created 
with GraphPad Prism 5 (GraphPad Software Incorporated, 




The participants were 24- to 44-year-old (avg. 32.6 ± 6.5) 
active male and female runners. The asymptomatic group 
consisted of nine runners (five males and four females) and 
the symptomatic group of eight runners (four males and 
four females). Overall, the symptomatic group reported 
to experience significantly (p < 0.001) more GI symptoms 
during running than the asymptomatic group. From the 
individual GI symptoms, flatulence (p < 0.05) and diarrhea 
(p < 0.001) were significantly more frequent during running 
in the symptomatic group than in the asymptomatic group. 
The baseline characteristics of the participants are listed in 
Table 1. In the symptom history questionnaire, 8 of the 17 
runners reported that they usually have loose stool or diar-
rhea after running. Two reports were from the asymptomatic 
group and six from the symptomatic group. The remaining 
seven runners in the asymptomatic group all reported to have 
normal stool consistency after running.
Running test
All participants were able to complete the running test. 
The average pace was 5:09 ± 0:48 min/km with no differ-
ence in pace between the groups. A total of five partici-
pants in the symptomatic group and three participants in the 
asymptomatic group reported to have experienced at least 
some degree of stomach pain during the running test. On the 
VAS, there was a non-significant trend for higher average 
stomach pain in the symptomatic group than in the asymp-
tomatic group (2.0 ± 2.1 vs. 0.30 ± 0.56, p = 0.061). All par-
ticipants in the symptomatic group and five participants in 
the asymptomatic group reported to have had at least one GI 
symptom during or following the running test. The symptom 
results of the running test are summarized in Table 2. Stool 
consistency after the run was loose in 10 of the 17 runners, 
with 5 reports from each group. The symptomatic group 
also reported two counts of hardened stools and one count 
of diarrhea. The asymptomatic group reported three counts 
of normal stool and one count of hardened stool.
Intestinal permeability
Intestinal permeability increased significantly (p < 0.05) 
in both study groups from baseline to after run measure-
ment (Fig.  2a). The mean iohexol permeability in the 
asymptomatic group was 0.20 ± 0.18% at baseline and 
0.39 ± 0.24% after running. In the symptomatic group, the 
mean iohexol concentration was 0.20 ± 0.07% at baseline 
and 0.36 ± 0.12% after running. There was no significant 
difference in the increase in permeability between the symp-
tomatic and asymptomatic group.
Table 1  Baseline characteristics of participants
1—never experience symptoms; 2—rarely experience symptoms 
(< 10% of runs); 3—sometimes experience symptoms (50% of runs); 
4—often experience symptoms (> 50% of runs); 5—always experi-
ence symptoms (> 90% of runs); age and symptom frequencies are 





Age 34.6 ± 6.1 30.4 ± 6.6 0.196
Symptom frequency 1.9 ± 0.33 3.9 ± 0.64 < 0.001
Frequency of individual symptoms
 Stomach pain 1.8 ± 0.44 2.3 ± 1.0 0.261
 Nausea 1.6 ± 0.53 2.1 ± 0.83 0.109
 Throwing up 1.3 ± 0.50 1.5 ± 0.53 0.517
 Bloating 1.9 ± 0.78 2.4 ± 1.1 0.295
 Burping 1.6 ± 0.73 2.3 ± 1.0 0.127
 Flatulence 2.1 ± 0.93 3.5 ± 1.1 0.012
 Heartburn 1.4 ± 0.73 2.0 ± 1.2 0.259
 Liquid in stomach 1.9 ± 0.33 2.5 ± 0.53 0.017
 Diarrhea 1.6 ± 0.53 3.8 ± 0.89 < 0.001
 Constipation 1.3 ± 0.50 1.3 ± 0.46 0.728
 Sum of symptom scores 18.3 ± 3.7 27.4 ± 4.3 < 0.001
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Serum I-FABP
In the asymptomatic group, serum I-FABP concentrations 
were significantly (p < 0.05) higher following the running 
test (804 ± 599 pg/ml) compared to the baseline values 
(314 ± 152 pg/ml) (Fig. 2b). In the symptomatic group, 
there was a trend for higher serum I-FABP concentrations 
after running but it did not reach statistical significance 
(baseline: 389 ± 327 pg/ml; after run: 961 ± 949 pg/ml). 
There were no significant differences in serum I-FABP 
concentrations between the groups.
Serum zonulin
Running induced a significant increase in serum zonu-
lin concentrations in the asymptomatic group (baseline: 
53.2 ± 26.3 ng/ml; after run: 70.4 ± 16.7 ng/ml; p < 0.05) 
(Fig. 2c). Serum zonulin concentrations were also signifi-
cantly (p < 0.05) higher in the asymptomatic group than in 
the symptomatic group (51.3 ± 14.6 ng/ml) following the run 
(Fig. 2c). There were no significant differences in baseline 
zonulin concentrations between the groups.
Serum LPS
Serum LPS activity did not increase from baseline after 
the running test (Fig. 3a). Serum LPS activity was signifi-
cantly (p < 0.01) higher at baseline in the symptomatic group 
(0.767 ± 0.119 EU/ml) than in the asymptomatic group 
(0.567 ± 0.124 EU/ml) (Fig. 3a). There was no significant 
difference in serum LPS activity between the groups after 
the run.
Fecal calprotectin
There were no significant differences in fecal calprotectin 
concentrations between the groups at baseline or after the 
run (Fig. 3b). In the asymptomatic group, there were four 
samples in total (three from baseline, one after run) where 
calprotectin concentrations were below the assay detection 
limit (< 5 g/kg) and thus were assigned the value 5 g/kg.
Discussion
The primary aim of this study was to measure running-
induced changes in intestinal permeability and examine their 
possible association with running-induced GI symptoms. 
Table 2  Pace, stomach pain, and symptom frequency in the two 
groups during and following the running test
Pace and stomach pain listed as means ± standard deviations, individ-
ual GI symptoms are reported as the number of study subjects in the 
group reporting such symptom
Asymptomatic Symptomatic p
n 9 8
Pace (min/km) 5:12 ± 0:59 5:06 ± 0:39 0.821
Stomach pain (VAS, cm) 0.30 ± 0.56 2.0 ± 2.1 0.061
Frequency of individual 
symptoms
 Nausea 0/9 3/8





 Liquid in stomach 0/9 1/8
 Diarrhea 1/9 3/8
 Constipation 1/9 2/8
 Subjects that reported at 
least one GI symptom
5/9 8/8
a b c
Fig. 2  Running induced a significant increase in intestinal perme-
ability to iohexol in both study groups (a). Running also increased 
serum I-FABP concentrations but this increase reached statisti-
cal significance only in the asymptomatic group (b). Serum zonulin 
increased significantly in the asymptomatic group following the run 
(c). Circles represent baseline values with lines indicating the change 
from baseline to after run values. n = 9 in the asymptomatic group in 
all, n = 8 in the symptomatic group in all. *p < 0.05
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Our results show that running induces a significant increase 
in urinary iohexol excretion for 24 h indicating increased 
intestinal permeability. This finding adds to the current 
literature that has shown mixed results when investigating 
exercise-induced changes in intestinal permeability (Ryan 
et al. 1996; Pals et al. 1997; van Nieuwenhoven et al. 1999; 
Marchbank et al. 2011; van Wijck et al. 2011; Zuhl et al. 
2015; Davison et al. 2016; JanssenDuijghuijsen et al. 2016). 
However, we did not observe any differences in intestinal 
permeability between asymptomatic and symptomatic run-
ners. To our knowledge, this is the first study that directly 
compares exercise-induced alterations in intestinal permea-
bility in asymptomatic and symptomatic runners. Previously, 
van Nieuwenhoven et al. (2004) showed that symptomatic 
athletes exhibit significantly higher intestinal permeability 
after cycling than asymptomatic athletes but this compari-
son was made based on historical asymptomatic controls. 
Overall, the literature regarding the relationship between 
exercise-induced GI symptoms and increased intestinal 
permeability is scarce. Most studies that have directly 
measured exercise-induced changes in intestinal perme-
ability do not report the occurrence of GI symptoms during 
exercise or vice versa. This is probably due to difficulties 
in accurately characterizing and measuring individual GI 
symptoms during different exercise intensities and dura-
tions. This was certainly a limitation in our study as well. 
Although we achieved a good separation between the two 
groups at baseline, we observed no clear differences in the 
occurrence of GI symptoms during or after the running test 
between the groups. This discrepancy could be due to sev-
eral factors. First, the subjects in the asymptomatic group 
reported stomach pain, other GI symptoms, and changes 
in stool consistency at a higher frequency than expected 
based on their background questionnaire. In contrast, three 
symptomatic athletes did not experience any stomach pain 
during the running test. These findings highlight the difficul-
ties in assigning athletes solely as either asymptomatic or 
symptomatic and assessing the occurrence of GI symptoms. 
Second, although suggested to run at challenging pace, the 
athletes determined their running pace themselves which 
might have led to variation in individual running intensities 
and subsequently affected the occurrence of GI symptoms. 
Third, excluding stomach pain, we gathered data mainly on 
symptom occurrence so we could not detect any possible 
differences in symptom severity between the groups. None-
theless, considering that all but two study subjects exhibited 
increased intestinal permeability after running, our results 
imply that increase in intestinal permeability is a normal 
response to running and it does not appear to correlate with 
the occurrence of GI symptoms.
Mature enterocytes express I-FABP and upon cellular 
damage, they release I-FABP into circulation (Adriaanse 
et al. 2013). Previous studies have shown that the extent of 
splanchnic hypoperfusion during exercise correlates with 
serum I-FABP concentrations (van Wijck et al. 2011) and 
that the small intestine is more prone to intestinal ischemia 
than the colon (Hundscheid et al. 2015). Together these 
findings suggest that in our study, the elevated serum con-
centrations of I-FABP after the running test stem from 
exercise-induced intestinal ischemia. Whether this explains 
the observed increase in intestinal permeability is an inter-
esting question. It is important to note that we measured 
intestinal permeability with a single 24-h urine collection 
and thus cannot distinguish between small intestinal and 
colonic permeability. However, Halme et al. (2000) have 
previously shown that iohexol absorption is constant along 
the intestinal tract with equal amounts of iohexol present 
in two 12-h urine fractions. Additionally, other studies that 
have reported increased intestinal permeability after exercise 
have employed measurement times ranging from 1 to 5 h 
a b
Fig. 3  Running did not increase serum LPS (a) or fecal calprotectin 
concentrations (b) from baseline. However, the symptomatic group 
exhibited significantly higher serum LPS concentrations at baseline 
than the asymptomatic group (a). There was also a trend for increased 
fecal calprotectin concentrations after running in the symptomatic 
group (b). Circles represent baseline values with lines indicating the 
change from baseline to after run values. n = 9 in the asymptomatic 
group in all, n = 8 in the symptomatic group in all. *p < 0.05
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(Pals et al. 1997; Marchbank et al. 2011; van Wijck et al. 
2011; Zuhl et al. 2015; Davison et al. 2016; JanssenDuij-
ghuijsen et al. 2016) suggesting increased small intestinal 
permeability. Thus, it is likely that the observed increase in 
intestinal permeability is a result of running-induced small 
intestinal damage.
Conceivably, small intestinal damage and increased intes-
tinal permeability could lead to elevated blood LPS activity. 
Indeed, several studies have reported elevated blood LPS 
activity after exercise (Brock-Utne et al. 1988; Bosenberg 
et al. 1988; Jeukendrup et al. 2000; Ashton et al. 2003; 
Moncada-Jimènez et al. 2009; Lim et al. 2009; Gill et al. 
2015), but whether this increase is the result of compro-
mised intestinal barrier function is unclear. In our study, 
running-induced increase in intestinal permeability did 
not result in increased serum LPS activity. This finding is 
similar to Yeh et al. (2013) who showed that running in 
cool temperature (22 °C) increases intestinal permeability 
(measured as plasma concentrations of tight junction protein 
claudin-3) but does not elevate plasma LPS concentrations. 
These findings suggest that increased intestinal permeability 
alone does not contribute to exercise-induced increase in 
blood LPS activity.
Whether elevated blood LPS activity contributes to the 
development of GI symptoms during exercise is still uncer-
tain. Previously, Brock-Utne et al. (1988) made an intriguing 
discovery when they reported that ultramarathon runners 
who had low or normal plasma LPS levels after running 
experienced less GI symptoms and recovered quicker than 
runners with high LPS values. However, subsequent studies 
have not been able to establish a clear correlation between 
serum LPS levels and GI symptoms during exercise (Jeuke-
ndrup et al. 2000; Moncada-Jimènez et al. 2009; Gill et al. 
2015). Interestingly, we found that the symptomatic run-
ners had higher serum LPS activity at rest than the asymp-
tomatic runners. This finding raises the question whether 
some underlying cause, such as nutrition (Kallio et al. 2015) 
or inadequate adaptation mechanisms to training (Bosenberg 
et al. 1988; Lim et al. 2009), leads to higher serum LPS 
activity at rest in symptomatic athletes and subsequently 
makes them susceptible to GI symptoms during exercise. 
Overall, the question regarding the relationship between 
compromised intestinal barrier, blood LPS activity, and GI 
symptoms during exercise remains open and warrants more 
research.
Exercise-induced intestinal damage and increased LPS 
leakage into circulation could trigger an inflammatory 
response. Multiple studies have shown that fecal calprotec-
tin acts as a reliable marker of inflammation or damage in 
the gastrointestinal tract (Konikoff and Denson 2006). Our 
results show a non-significant trend for higher fecal calpro-
tectin concentrations after running suggesting possible acti-
vation of inflammatory cascades in the intestinal mucosa. 
Van Wijck et al. (2011) findings support this conclusion as 
they showed previously that fecal calprotectin concentra-
tions rise after 60 min of cycling at high intensity. Interest-
ingly, although there was not a significant difference, the 
average fecal calprotectin after running was twice as high 
in the symptomatic group as in the asymptomatic group. 
This is an interesting trend and taken together with previ-
ous reports that have described a correlation with increased 
pro-inflammatory cytokines and GI symptoms during exer-
cise (Jeukendrup et al. 2000; Gill et al. 2015), highlights 
the possible role of inflammation in mediating some of the 
detrimental effects of exercise on the GI tract.
We also examined the serum concentration of zonulin, an 
endogenous protein known to regulate intestinal permeabil-
ity. The asymptomatic group exhibited significantly elevated 
serum zonulin levels after running compared to the symp-
tomatic group but the meaning of this finding is difficult to 
interpret. To our knowledge, only one study has previously 
examined the effects of exercise on serum zonulin concen-
trations and they reported no changes after high-intensity 
interval cycling (JanssenDuijghuijsen et al. 2016).
In conclusion, running for 90 min at a challenging pace 
induced a significant increase in intestinal permeability. 
However, we did not observe any differences between 
asymptomatic and symptomatic runners. The lack of differ-
ence in GI symptom occurrence during running between the 
study groups emphasizes the difficulty of assessing exercise-
induced GI symptoms and the need for more robust methods 
to identify asymptomatic and symptomatic athletes. Nev-
ertheless, the fact that almost all studied athletes exhibited 
increased intestinal permeability, whether they experienced 
GI symptoms or not, indicates that intestinal permeability 
changes alone do not account for GI symptom development 
during running.
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